Apolipoprotein A I (APOA1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Apolipoprotein A I (APOA1) – Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein A I (APOA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein A I (APOA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Apolipoprotein A I (APOA1)

The report reviews Apolipoprotein A I (APOA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Apolipoprotein A I (APOA1) targeted therapeutics and enlists all their major and minor projects

The report assesses Apolipoprotein A I (APOA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Apolipoprotein A I (APOA1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Apolipoprotein A I (APOA1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Apolipoprotein A I (APOA1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arisaph Pharmaceuticals, Inc.

Cerenis Therapeutics Holding SA

CSL Limited

Esperion Therapeutics, Inc.

KineMed, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Apolipoprotein A I (APOA1) Overview 6

Therapeutics Development 7

Apolipoprotein A I (APOA1) - Products under Development by Stage of Development 7

Apolipoprotein A I (APOA1) - Products under Development by Therapy Area 8

Apolipoprotein A I (APOA1) - Products under Development by Indication 9

Apolipoprotein A I (APOA1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Apolipoprotein A I (APOA1) - Products under Development by Companies 12

Apolipoprotein A I (APOA1) - Products under Development by Universities/Institutes 14

Apolipoprotein A I (APOA1) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Apolipoprotein A I (APOA1) - Companies Involved in Therapeutics Development 23

Arisaph Pharmaceuticals, Inc. 23

Cerenis Therapeutics Holding SA 24

CSL Limited 25

Esperion Therapeutics, Inc. 26

KineMed, Inc. 27

Apolipoprotein A I (APOA1) - Drug Profiles 28

4-WF - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ARI-1778 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CER-001 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

CER-522 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CSL-112 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

D-4F - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

KM-011 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Apolipoprotein A I (APOA1) - Dormant Projects 39

Apolipoprotein A I (APOA1) - Discontinued Products 40

Apolipoprotein A I (APOA1) - Featured News & Press Releases 41

Sep 01, 2016: Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology Congress 2016 41

Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule 41

Jun 02, 2016: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS) 43

Jan 28, 2016: Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology 44

Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 45

Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients 45

Jul 15, 2015: Cerenis Therapeutics Announces the Results of the LOCATION Study 46

Nov 18, 2014: CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated 48

Nov 12, 2014: CSL Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque 48

Sep 03, 2014: Cerenis Receives EMA Orphan Drug Designations for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies 49

Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS 50

Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 51

Nov 21, 2013: CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development 52

Nov 05, 2012: Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option For Reducing Recurrent Heart Attack Risk, Early CSL Studies Show 53

Mar 15, 2011: Cerenis Initiates Phase II Study Of CER-001 In Acute Coronary Syndrome 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 23

Pipeline by Cerenis Therapeutics Holding SA, H2 2016 24

Pipeline by CSL Limited, H2 2016 25

Pipeline by Esperion Therapeutics, Inc., H2 2016 26

Pipeline by KineMed, Inc., H2 2016 27

Dormant Projects, H2 2016 39

Discontinued Products, H2 2016 40

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports